Assessment of Quality of Life in Non-small-cell Lung Cancer Patients by Patient-reported Outcome (PRO) -A Review of Phase III Trials-

Yuki Kumihashi(Rheumatology Consultants), Saburo Sone(Io Therapeutics (United States)), Hiroya Tada(Tokushima University), Hisatsugu Goto(Tokushima University), Hideki Tomimoto(Tokushima University), Momoyo Azuma(Tokushima University Hospital), Masaki Hanibuchi(Tokushima University), Takanori Kanematsu(Matsuyama Red Cross Hospital), Soji Kakiuchi(Tokushima Prefectural Central Hospital), Yasuhiko Nishioka(Tokushima University)
Haigan
January 1, 2010
10.2482/haigan.50.791
Cited by 0

Related Papers

Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations
|Cancer Research|2008|642
Expression profiles of non-small cell lung cancers on cDNA microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs
|Oncogene|2003|324
Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839)
|Human Molecular Genetics|2004|175
The Neuromedin U-Growth Hormone Secretagogue Receptor 1b/Neurotensin Receptor 1 Oncogenic Signaling Pathway as a Therapeutic Target for Lung Cancer
|Cancer Research|2006|134
Plakophilin 3 Oncogene as Prognostic Marker and Therapeutic Target for Lung Cancer
|Cancer Research|2005|124